XLRN
Acceleron Pharma
XLRN
XLRN
Delisted
XLRN was delisted on the 19th of November, 2021.
217 hedge funds and large institutions have $4.32B invested in Acceleron Pharma in 2020 Q1 according to their latest regulatory filings, with 64 funds opening new positions, 53 increasing their positions, 77 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
14% less call options, than puts
Call options by funds: $54.7M | Put options by funds: $63.9M
31% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 77
Holders
217
Holding in Top 10
9
Calls
$54.7M
Puts
$63.9M
Top Buyers
| 1 | +$77.3M | |
| 2 | +$74.1M | |
| 3 | +$71.9M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$56.2M |
| 5 |
Holocene Advisors
New York
|
+$31.3M |
Top Sellers
| 1 | -$92.3M | |
| 2 | -$60.1M | |
| 3 | -$58.6M | |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$45.8M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$45.4M |